Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $76.04, for a total transaction of $228,120.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Scott Biller also recently made the following trade(s):

  • On Wednesday, January 10th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total transaction of $195,000.00.
  • On Friday, December 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $60.79, for a total transaction of $130,455.34.

Agios Pharmaceuticals Inc (AGIO) opened at $74.26 on Friday. Agios Pharmaceuticals Inc has a 52 week low of $44.31 and a 52 week high of $82.96.

AGIO has been the topic of several analyst reports. Credit Suisse Group increased their price target on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 17th. SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Finally, Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and an average target price of $77.64.

Large investors have recently modified their holdings of the stock. QS Investors LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Agios Pharmaceuticals by 41.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 762 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $160,000. Cubist Systematic Strategies LLC lifted its stake in Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in Agios Pharmaceuticals by 74.8% in the 4th quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares during the last quarter. 82.67% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/09/agios-pharmaceuticals-inc-agio-insider-sells-228120-00-in-stock.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.